Discovering The Unique Properties of PTH1R: A Potential Drug Target and Biomarker

Target Name: PTH1R

NCBI ID: G5745

PTH1R

Discovering The Unique Properties of PTH1R: A Potential Drug Target and Biomarker

Parathyroid hormone (PTH) is a hormone produced by the parathyroid gland that plays a crucial role in regulating calcium levels in the body. Parathyroid hormone is produced in several parathyroid glands located in the neck, and its primary function is to regulate the levels of calcium in the blood. When the levels of calcium in the blood are too low, PTH is released to increase the levels of calcium in the blood, and when the levels are too high, PTH is released to decrease the levels of calcium in the blood. PTH is also involved in the regulation of bone density and the prevention of osteoporosis.

PTH has several variants, and one of the most interesting variants is PTH1R. PTH1R is a variant of PTH that has been shown to have unique functions and characteristics compared to other variants. In this article, we will discuss the properties of PTH1R and its potential as a drug target or biomarker.

PTH1R Variant

PTH1R is a single-chain protein that consists of 184 amino acids. It has a molecular weight of 21.9 kDa and a pI of 9.9. PTH1R has a unique feature that is not found in other PTH variants, and that is the presence of a 21-amino acid residue at its C-terminus. This residue is important for the stability and function of the protein.

Function

PTH1R has been shown to have unique functions and abilities compared to other PTH variants. One of the most significant functions of PTH1R is its ability to regulate bone density. PTH1R has been shown to play a role in the regulation of bone density by promoting the activity of the protein osteonectin. Osteonectin is a protein that is involved in bone formation and maintenance, and it has been shown to play a role in the development and maintenance of bone density.

In addition to its role in regulating bone density, PTH1R has also been shown to have a positive impact on bone health. Studies have shown that PTH1R has been shown to reduce the activity of a protein called RANKL, which is a protein that has been shown to contribute to the development of osteoporosis. RANKL has been shown to promote the breakdown of bone tissue, which can contribute to the development of osteoporosis. By reducing the activity of RANKL, PTH1R has been shown to have a positive impact on bone health.

PTH1R has also been shown to have a role in the regulation of calcium levels in the body. Studies have shown that PTH1R has been shown to regulate the levels of calcium in the blood by controlling the activity of a protein called Ca2+-ATPase. Ca2+-ATPase is a protein that is involved in the regulation of calcium levels in the body, and it has been shown to play a role in the development of osteoporosis.

PTH1R as a Drug Target

PTH1R has been shown to have a unique function and a positive impact on several aspects of health, which makes it an attractive drug target. One of the most promising strategies for targeting PTH1R is the use of small molecules that can modulate its activity.

small molecules such as inhibitors, regulators, or modulators can be used to modulate PTH1R activity and have a positive or negative impact on the regulation of calcium, bone density, and osteoporosis.

PTH1R as a Biomarker

PTH1R has also been shown to be a potential biomarker for several diseases, including osteoporosis, bone fractures, and

Protein Name: Parathyroid Hormone 1 Receptor

Functions: Receptor for parathyroid hormone and for parathyroid hormone-related peptide. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and also a phosphatidylinositol-calcium second messenger system

The "PTH1R Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTH1R comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets